Lexology January 4, 2024
Hogan Lovells

The annual J.P. Morgan Healthcare Conference (JPM) provides a unique opportunity to make connections among life sciences and health care emerging companies, pharma/biotech companies, investors, and advisors.

Despite continued perceived economic headwinds, cutting edge research continues to provide new opportunities for life saving therapies for patients. However, early development programs for advanced medicines using innovative data strategies and enabling technologies inherently face many challenges and even more so for emerging companies, whose founders and executive officers, board members and investors must prioritize often limited resources across multiple layers of business decisions.

Management teams can take a number of steps to ensure that engagement with the U.S. Food and Drug Administration (FDA) is integrated into their strategic plan in order to...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Conferences / Podcast, FDA, Govt Agencies, Trends
FDA issues flu vaccine recommendations: 5 respiratory updates
5 Digital Health Areas To Be Impacted By The FDA Layoffs
FDA Approves First Biosimilar to Omalizumab
Trump's Nominees to Run FDA, NIH Get Greenlighted by Senate Committee
FDA Debuts a New Communications and Compliance Tool for Device Data Integrity Concerns

Share This Article